Verastem Oncology Announces Positive Updated Results from RAMP 205 Evaluating Avutometinib Plus Defactinib in Combination with Standard-of-Care Chemotherapy in First-Line Metastatic Pancreatic Cancer
Go back to Verastem Oncology Announces Positive Updated Results from RAMP 205 Evaluating Avutometinib Plus Defactinib in Combination with Standard-of-Care Chemotherapy in First-Line Metastatic Pancreatic Cancer| VERASTEM SHS (NASDAQ: VSTM) | Delayed: 8.08 -0.12 (1.46%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $8.20 | 52 Week High | $2.43 | |||
| Open | $8.20 | 52 Week Low | $1.05 | |||
| Day High | $8.54 | P/E | N/A | |||
| Day Low | $7.89 | EPS | $-1.79 | |||
| Volume | 4,366,393 | |||||
